Our Take
The premium paid (24% above close, 26x FY27 EBITDA) sits well below Bio-Techne's historical multiples—a signal that investors see limited upside from the vertical combination alone.
Why it matters
Life science tool consolidation is accelerating. Merck KGaA's third-largest biotech M&A deal this year reflects a push to control the entire customer journey from research labs to manufacturing floors, a strategy that assumes integrated workflows command pricing power.
Do this week
Life science teams: audit your supplier concentration risk before the deal closes (late 2026) so you can lock volume commitments or explore alternatives while both companies still operate independently.
Merck KGaA acquires Bio-Techne for $11.3 billion
German chemical and pharma conglomerate Merck KGaA agreed to buy Minneapolis-based Bio-Techne Corporation for $11.3 billion in cash, the companies announced today. The deal is the third-largest biotech M&A transaction announced in 2025, behind CVC Capital Partners' €10.7 billion bid for Recordati and Sun Pharmaceutical's planned $11.75 billion acquisition of women's health spinout Organon.
Bio-Techne generated net sales of $1.2 billion in its fiscal year ended June 30, 2025, and operates 34 global locations with 15 manufacturing facilities across the U.S., Canada, U.K., Switzerland, and China. The company employs 3,000 people, with approximately 2,300 in the U.S. Merck KGaA's Life Science segment reported €8.98 billion ($10.36 billion) in revenue last year.
The acquisition adds three product lines to Merck KGaA's existing research and bioprocessing platforms: multiomics offerings, the ProteinSimple line of automated protein detection instruments, and RNAscope spatial biology and in-situ hybridization technologies. Bio-Techne also holds 19.9% of Wilson Wolf, a cell culture device manufacturer, and has a forward contract to acquire the remaining stake in January 2028.
Both boards approved the transaction. The deal is expected to close by late 2026 or early 2027, subject to regulatory clearance and Bio-Techne shareholder approval. Merck KGaA said the acquisition will be immediately accretive to EBITDA pre-margin and add to earnings per share by year three post-close. The company plans €140 million (approximately $159.3 million) in cost synergies, fully realized by year three.
The acquisition signals modest market confidence in vertical integration
Bio-Techne shares rose 19.8% on the announcement to $70.53, a 24% premium to Wednesday's close and a 36% premium to the one-month volume-weighted average price. However, analysts flagged concern about valuation. The deal values Bio-Techne at 26x the Street's FY27 EBITDA forecast, compared to 16x for the broader life science tools peer group. Leerink Partners analyst Puneet Souda noted that Bio-Techne historically traded at significantly higher multiples given its 80%-plus consumables revenue mix and 70%-plus gross margins.
This is Merck KGaA's latest major acquisition in a strategy that has cost the company more than $35 billion over the past 15 years, including Millipore (2010), Sigma-Aldrich (2014), Versum Materials (2019), and SpringWorks Therapeutics (2023). The pattern suggests a bet that owning both upstream research tools and downstream bioprocess technologies allows Merck KGaA to offer integrated workflows that lock in customer relationships across the drug development and manufacturing value chain.
The muted investor response to the premium paid suggests the market remains skeptical that vertical scale in life science tools translates to durable pricing power. Analysts suggested that peer companies, particularly Revvity, may see near-term benefit from the announcement as the market reprices competing standalone players.
What to watch before the deal closes
The 18-month integration window creates a window of opportunity for existing Bio-Techne and Merck KGaA customers to negotiate terms. Customers heavily dependent on either company's tools should audit their supply contracts now and identify alternative suppliers or lock in multi-year volume agreements before the deal closes. Organizations evaluating ProteinSimple instruments, RNAscope assays, or cell culture devices should confirm pricing and support continuity post-acquisition.
For procurement teams in biotech and pharma, the transaction reinforces a longer-term trend: consolidation in life science tools reduces the number of qualified vendors. Plan your supplier diversity strategy and evaluate in-house capabilities or partnerships with smaller, independent tool makers before more options disappear.